Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Caprelsa

- PMLiVE

AstraZeneca’s Voydeya granted FDA approval for rare blood disease PNH

Up to 20% of patients treated with C5 inhibitors experience clinically significant extravascular haemolysis

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

AstraZeneca’s Ultomiris receives FDA approval to treat rare autoimmune disease NMOSD

Neuromyelitis optica spectrum disorder is estimated to affect approximately 6,000 adults in the US

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

AstraZeneca’s Tagrisso combination shows promising overall survival trend in phase 3 lung cancer study

An estimated 2.4 million people globally are diagnosed with lung cancer every year

- PMLiVE

AstraZeneca to acquire Fusion Pharmaceuticals in deal worth $2.4bn

The transaction includes a potential new treatment for metastatic castration-resistant prostate cancer

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

- PMLiVE

New technique enables study of immune response to cancer using archived tissue samples

FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples

- PMLiVE

AstraZeneca expands rare disease pipeline with $1.05bn Amolyt Pharma acquisition

The deal gives the company access to a late-stage candidate being evaluated for hypoparathyroidism

- PMLiVE

Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis

Amlitelimab could potentially offer treatment for a range of other immune-mediated diseases and inflammatory disorders

- PMLiVE

AstraZeneca announces plans to invest £650m in UK to boost life sciences sector

The investment will also help to enhance public health protection and pandemic preparedness in the UK

- PMLiVE

Gilead and Merus announce oncology partnership worth over $1.5bn

The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links